Charles Minto, FANZCA, PhD

• Vice President, World Society of Intravenous Anaesthesia.

PO Box 267
Beecroft, NSW 2119
Australia

E-mail: charlesminto@optusnet.com.au

Within the past ten years, I have received honararia (e.g., a bottle of wine) for speaking engagements about propofol and alfentanil (from AstraZeneca, Australia), remifentanil (GlaxoWelcome, New Zealand), and about target controlled infusions (AstraZeneca, Australia; Cardinal Health, New Zealand; Pharmatel Fresenius Kabi, Australia).

I have signed confidentiality agreements with GE, J&J, Fresenius Kabi and Cardinal Health. I have not been paid as a consultant to any company. I do not receive any royalties from any company. I do not have any financial interests in any company. See also my disclaimer.

Thomas Schnider and I own the domain names http://opentci.org and http://opentci.com. We pay for all of the costs associated with the running of this website. We do not receive any income from any company or organisation associated with the running of this website.

Thomas Schnider and I are co-authors of the pharmacokinetic-pharmacodynamic modeling software PKPD Tools for Excel and for the OpenGL applications for teaching compartment model and response surface model concepts. We receive no sponsorship from industry for these programs. We charge no licence fees for these programs. They are available for free from http://pkpdtools.com.